Vol. 5 No. 3 (2017): December 2017

Published: 2017-10-31

Editorial

New treatment opportunities for patients with advanced and/or metastatic thyroid cancer

Laura D. Locati, Salvatore Alfieri, Lisa Licitra

3-5
- PDF

Review

Immunotherapy and non-small cell lung cancers

Letizia Laera, Silvia Novello

6-10
- PDF

Pro & Cons editorial

Secondary de-bulking surgery in recurrent ovarian cancer

Philipp Harter, Nicoletta Colombo, Claudia Marchetti, Federica Tomao

11-13
- PDF

Breaking from the Lab

Predictive biomarkers of response for PD-1/PD-L1 inhibitors: a cumbersome gold rush

Andrea Vingiani, Massimo Barberis, Elena Guerini-Rocco

14-19
- PDF

Clinical original article

Real-world safety profile of abiraterone acetate in patients with castration-resistant prostate cancer and cardiovascular comorbidities: a retrospective, single center study

Giovanni Fuca, Elena Verzoni, Alessia Mennitto, Michele Prisciandaro, Raffaele Ratta, Giuseppe Procopio

20-24
- PDF
SRSF2 mutations in epithelial ovarian cancer

Milena Sabrina Nicoloso, Monica Schiappacassi, Alessandra Dall’Acqua, Sara D’Andrea, Sara Benevol, Roberto Sorio, Vincenzo Canzonieri, Giorgio Giorda, Gustavo Baldassarre

25-29
- PDF

Meet the expert

Case 1 – Successful resection after FOLFIRI plus cetuximab therapy for unresectable colorectal cancer with multiple liver metastases

Anna Nappi, Carmela Romano, Gugliemo Nasti, Fotios Loupakis

30-35
- PDF
Case 2 – Adjuvant therapy in a patient with HER2-positive early breast carcinoma

Raúl Márquez Vázquez, Antonio González Martín, Javier Cortés

36-40
- PDF

Methodological corner

Trial designs for the development of new drugs

Cecilia Orbegoso, Eleonora Ghisoni, Susana Banerjee

41-44
- PDF

Correspondence

Letter to the Editor

Patricia Pautier

45-47
- PDF